Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 3Neuroendocrine Tumors 3Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Liver Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2Uveal Melanoma 1Thyroid Neoplasms 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neoplasms 1Nelson Syndrome 1Myelodysplastic Syndromes 1Meningioma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Hematologic Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5copper dotatate CU-64 3Magnetic Resonance Spectroscopy 3lanreotide 2gallium Ga 68 dotatate 2Nivolumab 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Carboplatin 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1regorafenib 1pembrolizumab 1pasireotide 1irinotecan sucrosofate 1folfirinox 1cabozantinib 1abemaciclib 1X-Rays 1Temozolomide 1Somatostatin 1Resveratrol 1Radiosurgery 1Octreotide 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastro-enteropancreatic neuroendocrine tumor × pasireotide × Clear all
NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡